• Romidepsin (FK228) Cancer Research Workflows

  2026-08-18

  Romidepsin (FK228) is a selective class I HDAC probe for connecting chromatin remodeling with cell-cycle and apoptosis phenotypes. This workflow shows how to control solvent, dose, timing, target-engagement assays, and proteomic validation while using the Platycodin D study as a complementary model for mechanism-first cancer research.

• X-Gal Workflows for Cloning and Reporter Assays

  2026-08-17

  X-Gal converts β-galactosidase activity into a practical visual decision point for clone selection, reporter validation, and assay troubleshooting. This guide connects blue-white colony screening with activity-linked research while clearly separating established cloning uses from exploratory olfactory biology applications.

• Cytochalasin D: Actin Polymerization Inhibitor

  2026-08-17

  Cytochalasin D is a potent actin polymerization inhibitor used to perturb cytoskeletal dynamics, cell-cycle signaling, cancer-cell behavior, and virus-associated cellular processes. The B6645 product information reports a 25 nM IC50, while ocular nanoparticle research provides a relevant framework for testing actin dependence during cellular uptake.

• Photothermal Therapy and CD47 Blockade in OSCC

  2026-08-16

  A 2026 study shows that photothermal therapy (PTT) strengthens CD47 blockade in oral squamous cell carcinoma by supplying both a calreticulin-dependent “eat me” signal and improved macrophage access through extracellular matrix remodeling. The work provides a mechanistic framework for combining local thermal treatment with innate immune checkpoint inhibition in solid tumors.

• Gefitinib in Gastric Cancer Assembloid Assays

  2026-08-15

  Gefitinib (ZD1839) provides a mechanistically defined probe for EGFR signaling pathway inhibition in patient-derived gastric cancer assembloids. This article explains how matched tumor–stroma models can reveal response discordance, resistance biology, and assay-design requirements that conventional organoids may conceal.

• Danazol Workflows for Endocrine Research

  2026-08-14

  Danazol enables controlled interrogation of steroidogenesis, hypothalamic–pituitary–gonadal signaling, and androgen-responsive biology. This workflow translates a recent rat puberty model into practical cell, tissue, and translational assay decisions while emphasizing formulation, controls, and interpretation.

• SC 79: Reliable Akt Assay Design

  2026-08-14

  Learn how SC 79, supplied as SKU B5663, can be integrated into cell viability, proliferation, cytotoxicity, and Akt signaling experiments. This scenario-based guide covers mechanism, controls, solvent handling, metabolic-model interpretation, and practical vendor selection.

• EdU Imaging Kits (Cy3) for VSMC S-Phase Assays

  2026-08-13

  EdU Imaging Kits (Cy3) convert DNA replication into a bright Cy3 signal without the DNA denaturation required by many BrdU workflows. This guide shows how to apply the assay to vascular smooth muscle cell phenotypic switching, quantify S-phase entry, and troubleshoot microscopy or flow-cytometry results.

• Angiotensin I: Applied Research Workflows

  2026-08-13

  Turn Angiotensin I into a controllable substrate challenge for ACE activity studies, antihypertensive drug screening, and mechanistic cardiovascular research. This workflow emphasizes peptide handling, quantitative Ang II readouts, interference-aware data processing, and practical troubleshooting.

• Aprotinin (BPTI): Mechanism and Research Use

  2026-08-12

  Aprotinin, also called bovine pancreatic trypsin inhibitor, is a reversible serine protease inhibitor used to study fibrinolysis, inflammation, and cardiovascular surgery blood management. Its reported IC50 values span 0.06–0.80 µM across target proteases and assay conditions, while formulation and storage requirements must be validated experimentally.

• CDC42 Polarity Controls Intestinal Stem Cell Fate

  2026-08-12

  The reference study identifies CDC42-dependent epithelial polarity as an upstream regulator of the intestinal stem cell to transit-amplifying cell transition. Using inducible genetic models and pathway perturbations, it places YAP/TAZ–Ereg–mTOR signaling downstream of polarity control and separates cell-fate rescue from restoration of epithelial architecture.

• MK-2206 Dihydrochloride for Akt Assays

  2026-08-11

  Use MK-2206 dihydrochloride to connect Akt phosphorylation measurements with cancer cell apoptosis, endothelial angiogenesis, and pathway-rescue experiments. This workflow translates extracellular-vesicle findings in hepatocellular carcinoma into practical dose, timing, control, and troubleshooting decisions.

• Pol II Degradation and Cell Death Beyond Transcription

  2026-08-11

  The bioRxiv preprint proposes that RNA polymerase II degradation can activate a regulated cell-death program that is mechanistically distinct from transcriptional shutdown alone. Its experimental framework separates loss of transcription from depletion of hypophosphorylated Pol IIA, offering a useful model for interpreting apoptosis-related pharmacology and cancer research assays.

• CAR Macrophage Programming for Peritoneal Metastasis

  2026-08-10

  Gu et al. develop a macrophage-targeted mRNA lipid nanoparticle platform for generating tailored CAR macrophages directly within the peritoneal cavity. Their comparison of 36 CAR designs identifies CD3ζ–TLR4 intracellular domains as a strong configuration that remodels the tumor microenvironment, expands TCF1+PD-1+ progenitor-exhausted CD8+ T cells, and improves the response to PD-1/PD-L1 blockade.

• Romidepsin (FK228) Workflows for Cancer Epigenetics

  2026-08-09

  Romidepsin (FK228) combines class I HDAC selectivity with practical potency for chromatin, apoptosis, and cell-cycle studies. This guide translates its use into reproducible dose-response, phenotyping, and proteomics workflows while showing how the RFC4–Notch study can strengthen mechanism-focused assay design.

11427 records 1/762 page Next 12345 下5页 Last page